Regulatory Roundup: Week of October 1, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: Week of October 1, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has launched BeSafeRx—Know Your Online Pharmacy, a national campaign designed to promote public awareness of fraudulent Internet pharmacies. The program offers consumers resources for educating themselves on FDA’s website at www.fda.gov/BeSafeRx. FDA warns that fake online pharmacies use sophisticated marketing tricks and that “less than 3% of online pharmacies meet state and federal laws.” FDA recommends consumers only purchase from online pharmacies located in the United States that require a valid doctor’s prescription, have a licensed pharmacist available, and are licensed with a state board of pharmacy.

FDA has released the following guidance documents:

Guidance for Industry, Acute Bacterial Otitis Media: Developing Drugs for Treatment (September 2012).

Guidance for Industry, Acute Bacterial Exacerbations of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease: Developing Antimicrobial Drugs for Treatment (September 2012).

Guidance for Industry, Complicated Intra-Abdominal Infections: Developing Drugs for Treatment, Draft Guidance (September 2012).

Guidance for Industry, Initial Completeness Assessments for Type II API DMFs Under GDUFA, Draft Guidance (October 2012).

On Oct. 1, 2012, the European Medicines Agency announced publication of the “EURD list,” a list of European Union reference dates and frequency of submission of periodic safety update reports. The EURD list includes active substances and combinations of active substances in drugs that are subject to different marketing authorizations.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here